Prostaglandin transporter inhibitors
View Patent ↗Provided are methods of inhibiting prostaglandin transporter (PGT) activity in mammals. Also provided are methods of determining whether a test compound is an inhibitor of a prostaglandin transporter. Additionally provided are compounds that inhibit prostaglandin transporter activity, and pharmaceutical compositions of those compounds. Methods of inhibiting COX-2 in a mammal are also provided. Additionally, methods of treating pain or inflammation in a mammal are provided.
1. A method of inhibiting prostaglandin transporter (PGT) activity in a mammal, the method comprising administering a compound to the mammal effective to inhibit PGT activity, wherein the compound has Formula I:
or a pharmaceutically acceptable salt, ester, or tautomer thereof, wherein R is a C 1 -C 15 straight or branched alkyl, a substituted alkyl, a cycloalkyl, a carboxyalkyl, a substituted cycloalkyl, a C 1 -C 15 straight or branched alkenyl, a substituted alkenyl, a cycloalkenyl, a substituted cycloalkenyl, a C 1 -C 15 straight or branched alkinyl, a substituted alkinyl, a cycloalkinyl, a substituted cycloalkinyl, a C 1 -C 10 straight or branched ether, a substituted ether, a cycloether, an ester, an amide, an acetyl, an aminal, an anhydride, an aryl, a substituted aryl, a heteroaryl, a substituted heteroaryl, a carboxyaryl, a heterocyclic group, a substituted heterocyclic group, a fused cycloalkyl, a substituted fused cycloalkyl, a fused heterocyclic group, a substituted fused heterocyclic group, a fused aryl, a substituted fused aryl, a fused heteroaryl, a substituted fused heteroaryl ring, or any combination thereof, optionally further comprising a hydroxy, an alkoxy, an aryloxy, an oxo, an ester, an ether, an amine, an azo, an azido, a nitro, an imine, an isothionate, a carbonyl, a peroxide, a halogen, a formyl, an acyl, a carboxy, an amido, a carbamoyl, a guanidino, a ureido, a amidino, a thiol, a mercapto, a sulfinyl, a sulfonyl and/or a sulfonamide.
2. The method of claim 1 , wherein R comprises a carboxyl or phenol group.
3. A method of inhibiting prostaglandin transporter (PGT) activity in a mammal, the method comprising administering a compound to the mammal effective to inhibit PGT activity, wherein the compound is
4. The method of claim 3 , wherein the compound is
5. The method of claim 3 , wherein the compound is
6. The method of claim 3 , wherein the compound is
7. The method of claim 3 , wherein the compound is
8. The method of claim 3 , wherein the compound is
9. The method of claim 3 , wherein the compound is
10. The method of claim 3 , wherein the compound is
11. The method of claim 3 , wherein the compound is
12. The method of claim 3 , wherein the compound is
13. The method of claim 3 , wherein the compound is
14. The method of claim 3 , wherein the compound is
15. The method of claim 3 , wherein the compound is
16. The method of claim 3 , wherein the compound is
17. The method of claim 3 , wherein the compound is
18. The method of claim 3 , wherein the compound is
19. The method of claim 3 , wherein the mammal is a human suffering from a disease or disorder at least partially mediated by a cyclooxygenase-2.
20. The method of claim 19 , wherein the disease or disorder involves pain and/or inflammation.
21. The method of claim 19 , wherein the disease or disorder is arthritis, fever, common cold, hypertension, glaucoma, slow wound healing, slow initiation of labor, dysmenorrhea, menstrual cramps, inflammatory bowel disease, Crohn's disease, emphysema, acute respiratory distress syndrome, asthma, bronchitis, chronic obstructive pulmonary disease, Alzheimer's disease, organ transplant toxicity, cachexia, allergic reactions, allergic contact hypersensitivity, cancer, tissue ulceration, peptic ulcers, gastritis, regional enteritis, ulcerative colitis, diverticulitis, recurrent gastrointestinal lesion, gastrointestinal bleeding, coagulation, anemia, synovitis, gout, ankylosing spondylitis, restenosis, periodontal disease, epidermolysis bullosa, osteoporosis, loosening of artificial joint implants, atherosclerosis, aortic aneurysm, periarteritis nodosa, congestive heart failure, myocardial infarction, stroke, cerebral ischemia, head trauma, spinal cord injury, neuralgia, neuro-degenerative disorders, autoimmune disorders, Huntington's disease, Parkinson's disease, migraine, depression, peripheral neuropathy, pain, gingivitis, cerebral amyloid angiopathy, nootropic or cognition enhancement, amyotrophic lateral sclerosis, multiple sclerosis, ocular angiogenesis, corneal injury, macular degeneration, conjunctivitis, abnormal wound healing, muscle or joint sprains or strains, tendonitis, skin disorders, myasthenia gravis, polymyositis, myositis, bursitis, burns, diabetes, tumor invasion, tumor growth, tumor metastasis, corneal scarring, scleritis, immunodeficiency diseases, sepsis, premature labor, hyporothrombinemia, hemophilia, thyroiditis, sarcoidosis, Behcet's syndrome, hypersensitivity, kidney disease, rickettsial infections, protozoan diseases, reproductive disorders or septic shock.
22. A compound that inhibits prostaglandin transporter activity, wherein the compound is
23. The compound of claim 22 , wherein the compound is
24. The compound of claim 22 , wherein the compound is
25. The compound of claim 22 , wherein the compound is
26. The compound of claim 22 , wherein the compound is
27. The compound of claim 22 , wherein the compound is
28. The compound of claim 22 , wherein the compound is
29. The compound of claim 22 , wherein the compound is
30. The compound of claim 22 , wherein the compound is
31. The compound of claim 22 , wherein the compound is
32. The compound of claim 22 , wherein the compound is
33. The compound of claim 22 , wherein the compound is
34. The compound of claim 22 , wherein the compound is
35. The compound of claim 23 , wherein the compound is
36. The compound of claim 23 , wherein the compound is
37. The compound of claim 23 , wherein the compound is
38. A pharmaceutical composition comprising the compound of claim 23 in a pharmaceutically acceptable excipient.